Halozyme Therapeutics, Inc. (HALO) has inked a global collaboration and license agreement with GSK plc (GSK) to develop subcutaneous formulations of multiple promising oncology targets.
Under the agreement, GSK has licensed Halozyme's ENHANZE drug delivery technology for the development and potential commercialization of subcutaneous administration of multiple oncology targets, including antibody drug conjugates (ADCs), as well as an option for additional future drug targets.
This marks the first ENHANZE agreement to include ADC targets, and the first clinical trial is expected to be initiated this year.
GSK will pay Halozyme an upfront amount and make potential future milestone payments. Halozyme will also be entitled to earn royalties on net sales of products developed using ENHANZE technology.
HALO closed Wednesday's trading at $66.35, up 0.73%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.